Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 12Withdrawn 2Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 14Sarcoma 2Other hematologic neoplasm 2Genitourinary 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1

Conditions

Dendritic Cell Sarcoma, Interdigitating 2

Interventions

Doxorubicin 5Cyclophosphamide 4Vincristine 3Temozolomide 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Injections 3polatuzumab vedotin 2liposomal doxorubicin 2glofitamab 2envafolimab 2anlotinib 2X-Rays 2Radiotherapy 2Prednisone 2Nivolumab 2Imatinib Mesylate 2Biopsy 2AZD 6244 2toripalimab 1surufatinib 1relmacabtagene autoleucel 1regorafenib 1pemigatinib 1pazopanib 1obinutuzumab 1montelukast 1irinotecan sucrosofate 1fludarabine 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Prednisone × Sarcoma × Clear all
NCT07231250 2025-11-19

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 2 Not yet recruiting
40 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT07034508 2025-06-24

A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Not yet recruiting
134 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡